Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.